Ligufalimab
Sponsors
Groupe Oncologie Radiotherapie Tete Cou, University of Texas Southwestern Medical Center, Groupe Oncologie Radiotherapie Tete et Cou
Conditions
Advanced Hepatocellular CarcinomaBiliary Tract CancerRefractory Hepatocellular CarcinomaSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)recurrent and/or metastatic squamous cell carcinoma of the head and neck
Phase 2
Phase 3
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Not yet recruitingNCT07264075
Start: 2026-04-01End: 2030-05-01Target: 780Updated: 2026-04-02
A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)
Not yet recruitingCTIS2025-522996-27-00
Target: 310Updated: 2025-12-19